Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study.
Jonathan W. Riess(University of California Davis Medical Center), David R. Gandara(University of California, Davis), Pasi A. Jänne(Harvard University), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Sukhmani K. Padda(Stanford University), Cloud P. Paweletz(Massachusetts General Hospital), Grace A. Heavey(Dana-Farber Cancer Institute), Jill Kolesar(University of Kentucky), Susan Groshen(USC Norris Comprehensive Cancer Center), Zofia Piotrowska(Global Cancer Institute), Primo N. Lara(UC Davis Comprehensive Cancer Center), Edward M. Newman(City of Hope), Jeffrey A. Moscow(National Cancer Institute), Conor Steuer(Emory University), Mark Krailo(Arcadia), Lynette M. Sholl(Brigham and Women's Hospital), Marianna Koczywas(City Of Hope National Medical Center), Chul Kim(Georgetown University), Heather A. Wakelee(Palo Alto Institute)
Cited by 12
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k